Short primer on how to analyze biotech stocks
Biotech investing has a reputation for being exciting — and brutal. The upside is obvious: one big drug approval can send a stock up 50–100% in a single day. But the path there is littered with failure. Roughly 90% of drugs that enter clinical testing never make it to market. It’s a capital-intensive, high-burn business where you’re essentially trying to find the one out of ten that survives.
If you want to play this game well, you can’t just love the science. You also have to understand the business model and the incentives around each drug launch.
Let’s hear it from a long-only life science PM, whose fund has consistently beaten its benchmark. You can access the article, my fund primers and deep dives in the premium section below.
My tools and insights for navigating public equity recruiting
Check out my other published articles:
📇 Connect with me: Instagram | Twitter | LinkedIn | YouTube
If you want to advertise in my newsletter, contact me 👇
If you enjoyed this article, please subscribe and share it with your friends/colleagues. Sharing is what helps us grow! Thank you.
Nice nice. Perfect timing!